MARKET

SNSS

SNSS

Sunesis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.360
+0.190
+16.24%
Closed 19:58 09/25 EDT
OPEN
1.170
PREV CLOSE
1.170
HIGH
1.480
LOW
1.170
VOLUME
3.43M
TURNOVER
--
52 WEEK HIGH
11.30
52 WEEK LOW
1.170
MARKET CAP
24.61M
P/E (TTM)
-0.0638
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Return On Capital Employed Overview: Sunesis Pharmaceuticals
During Q2, Sunesis Pharmaceuticals's (NASDAQ: SNSS) reported sales totaled $0.00. Despite a 9.43% in earnings, the company posted a loss of $6.34 million. Sunesis Pharmaceuticals collected $120.00 thousand in revenue during Q1, but reported earnings showed a $5.80 million loss.Why ROCE Is Significant
Benzinga · 09/03 13:55
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.Wells Fargo 2020 Virtual Healthcare Conference Date: Thursday, September 10 Time: 2:00 PM Eastern TimeOppenheimer
GlobeNewswire · 09/03 11:00
Sunesis Pharmaceuticals to reverse split shares 1:10
To regain compliance with Nasdaq's $1 minimum bid price listing requirement, Sunesis Pharmaceuticals ([[SNSS]] -32.0%) will execute 1:10 reverse stock split within the split ratio range of 1:2 and 1:12, after the
Seekingalpha · 09/02 17:49
Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective as of 5:00 p.m. Eastern
GlobeNewswire · 09/02 16:48
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stock
Seeking Alpha - Article · 08/28 18:30
Sunesis Pharmaceuticals Q2 EPS $(0.06), Inline
Sunesis Pharmaceuticals (NASDAQ:SNSS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.09) per share from the same period last
Benzinga · 08/11 20:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNSS. Analyze the recent business situations of Sunesis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNSS stock price target is 3.250 with a high estimate of 5.00 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 9.54M
% Owned: 52.75%
Shares Outstanding: 18.09M
TypeInstitutionsShares
Increased
6
34.97K
New
20
-2.58M
Decreased
10
427.55K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Non-Executive Chairman
James Young
Chief Executive Officer/Chief Financial Officer/Secretary/Director
Dayton Misfeldt
Executive Vice President
Adam Craig
Chief Accounting Officer/Vice President - Finance
Tina Gullotta
Director
Stephen Ketchum
Director
H. Ward Wolff
Independent Director
Steve Carchedi
Independent Director
Matthew Fust
Independent Director
Nicole Onetto
Independent Director
Homer Pearce
Independent Director
David Stump
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNSS
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sunesis Pharmaceuticals, Inc. stock information, including NASDAQ:SNSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNSS stock methods without spending real money on the virtual paper trading platform.